Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II biomarker study of upfront versus delayed dabrafenib + trametinib in BRAF-mutant unresectable or metastatic melanoma
2012-004577-12Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dabrafenib + trametinib and trametinib in melanoma (3 arms), sponsored by GSK. Primary endpoint: Percentage change of ERK phosphorylation score from baseline. Started Feb 2015; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2012-004577-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004577-12.